Latest news with #JournalofAlzheimer'sDisease
Daily Mirror
4 days ago
- Health
- Daily Mirror
Morning tea or coffee could slash risk of Alzheimer's disease
Your memory could be sharper simply down to what you drink The drink you consume every day could be giving you more benefits than you think. New research has linked moderate consumption of two drinks with slower declines in reasoning and memory among seniors. Published in the Journal of Alzheimer's Disease, researchers explored the link between tea and coffee consumption and long-term cognitive changes in older adults. The findings suggest that moderate coffee intake, along with moderate to high tea consumption, could be linked to a slower rate of cognitive decline. It also reveals that drinking these beverages may help safeguard against particular types of cognitive decline in older adults, particularly in areas like reasoning and problem-solving. In contrast, consuming four or more cups of coffee daily was linked to a quicker decline. In fact, "one study found that consuming up to 2.5 cups of coffee per day was linked to a lower risk of cognitive disorders, while for tea, a linear relationship was observed, where each additional daily cup was associated with an 11% reduction in risk." The study analysed data from 8,715 dementia-free participants in the UK, aged between 60 and 85, who were followed for an average of 9.11 years. People were excluded if they had medical conditions or were on medications that could affect cognitive health, such as Parkinson's disease, depression, diabetes, hypertension, or if they consumed more than 14 units of alcohol per week. In their study conclusion, researchers revealed "moderate coffee and both moderate and high tea intake were associated with slower declines in fluid intelligence over nearly a decade, suggesting potential cognitive benefits in older age. While the protective effects were more apparent for tea and moderate coffee intake, high coffee consumption (four or more cups per day) was linked to poorer outcomes." Despite some "limitations", the study notes that the results suggest "moderate consumption of coffee and tea may be protective against age-related cognitive decline. The researchers speculate that caffeine may be a key factor, noting that tea's lower caffeine content could explain why no upper limit for beneficial tea consumption was observed in this study." The study highlights that cognitive decline, especially from Alzheimer's disease, poses a major public health challenge in ageing populations. With this in mind, the experts stress that identifying lifestyle factors that can help preserve cognitive function and is essential.
Daily Record
04-08-2025
- Health
- Daily Record
Drinking three cups of coffee day could protect against cognitive decline, new study finds
A new study found coffee and tea consumption is linked to declines in memory and reasoning in people over 60 Scientists have discovered an unexpected link between cognitive decline and the amount of tea or coffee consumed daily by people over 60. They have pinpointed a 'sweet spot' of around three cups of either beverage to maintain mental sharpness. However, they also found that consuming more than four cups of coffee per day was associated with poorer results. Interestingly, those who drank tea had worse results at the beginning of the study, despite experiencing a slower decline thereafter. The reasons behind these connections between tea and coffee consumption and cognitive decline remain unclear. The researchers highlighted the need for further studies to unravel this mystery, but suggested it might be related to caffeine content, as reported by News Medical. In a single cup of tea, there's approximately 28mg to 45mg of caffeine, while a cup of coffee contains around 95mg. This could explain why high tea intake was associated with slower decline, whereas high coffee intake was linked to faster decline. Published in the Journal of Alzheimer's Disease, the research examined the long-term effects of tea and coffee consumption specifically on older adults. It tracked over 8,700 UK adults aged between 60 and 85 for just under a decade. The research took into account people with genetic predispositions for Alzheimer's disease, excluding those with other conditions that could influence the results such as Parkinson's, depression, diabetes, hypertension or consuming more than 14 units of alcohol per week. Participants were asked to disclose their coffee or tea consumption and were categorised into three groups; those who never drank it, those who consumed between one and three cups a day (moderate intake), and those with a high intake who had four or more cups daily. Their cognitive function was then evaluated using computerised tests which required them to solve verbal and numeric reasoning problems, testing their reaction time and memory, as well as a visual memory test using pair matching. People who either never drank coffee or had a moderate coffee intake exhibited a slower decline in their cognitive ability over time. However, those consuming four or more cups of coffee daily made more errors in pair matching as the years progressed, indicating they experienced a faster cognitive decline. On the flip side, people who had moderate to high tea consumption showed less decline compared to those that never drank tea. Drinking tea also didn't have any significant links to changes in reaction times, pair-matching errors or numerical memory. Researchers have highlighted previous studies that consistently demonstrate tea's superior cognitive benefits compared to coffee. Notably, a 2022 Chinese study found that consuming more than four cups of tea daily can reduce cognitive decline. However, the study does have its limitations as it failed to consider different brewing methods. Therefore, there's no data on whether participants were drinking decaffeinated or caffeinated coffee, what types of tea they were sipping, or how much milk and sugar they added to their brews.
News18
25-07-2025
- Health
- News18
Can You Get Alzheimer's In Your 20s? Aneet Padda's Character Explores It In Saiyaara
Last Updated: Saiyaara explores the story of a 22-year-old woman diagnosed with early-onset Alzheimer's. The movie has sparked an important conversation around the early onset of this disease. The new Bollywood sensation Saiyaara is doing more than breaking box office records. The film, led by newcomer Aneet Padda and Ahaan Panday, follows the heartbreaking journey of a 22-year-old woman diagnosed with early-onset Alzheimer's, a form of dementia rarely seen in young people. With its emotionally rich storytelling and bold subject choice, Saiyaara has not only touched audiences deeply but also triggered real-world questions: Can Alzheimer's really affect people in their twenties? While Alzheimer's disease is typically associated with individuals over the age of 65, a rarer form known as early-onset or younger-onset Alzheimer's can develop decades earlier. According to Johns Hopkins University, this condition has been diagnosed in people as young as their 30s and, in extremely rare cases, even in their 20s. There are two primary forms: The exact triggers for Alzheimer's remain elusive, but researchers point to the accumulation of toxic proteins in the brain – specifically beta-amyloid plaques and tau tangles. These interfere with normal brain function, causing irreversible damage to areas responsible for memory, speech, and judgment. While these protein build-ups can occur naturally with age, those with Alzheimer's experience them in higher volumes and at a much earlier stage. Genetics, environmental exposure, and lifestyle choices are all believed to influence the onset and severity of the disease. Recognising The Early Warning Signs Of Alzheimer's Disease Early-onset Alzheimer's often mirrors the symptoms of its later-onset counterpart. These include: In many cases, it's family or close friends who spot these signs before the individual does. Because early-onset Alzheimer's is so uncommon, especially in young adults, symptoms may be dismissed or misdiagnosed. Can You Really Get Alzheimer's In Your 20s? Though almost unheard of, there have been documented instances of Alzheimer's in people under 30. A 2022 study published in the Journal of Alzheimer's Disease reported the case of a 19-year-old in China diagnosed with the condition. Such occurrences are extremely rare and often linked to inherited genetic mutations. Who Faces The Highest Risk Of Alzheimer's Disease? Certain factors increase the likelihood of developing early-onset Alzheimer's, including: How Can Alzheimer's Disease Be Treated? There is currently no cure for Alzheimer's, but medical advancements have led to medications that may help manage symptoms or slow the disease's progression – particularly if diagnosed early. Maintaining cardiovascular health, staying mentally and socially active, and prioritising sleep and nutrition may all contribute to reducing the risk or delaying the onset. view comments Location : Delhi, India, India First Published: July 25, 2025, 10:10 IST News lifestyle » health-and-fitness Can You Get Alzheimer's In Your 20s? Aneet Padda's Character Explores It In Saiyaara Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Newsweek
25-06-2025
- Health
- Newsweek
Ozempic Linked to Significant Reduction in Dementia—Study
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Semaglutide, the active ingredient in diabetes medications Ozempic and Wegovy, was associated with a significantly reduced risk of developing Alzheimer's disease-related dementia among patients with type 2 diabetes, a recent study reported. A new study published in the Journal of Alzheimer's Disease analyzed the medical records of over 1.7 million U.S. adults and found that semaglutide users experienced a notably lower risk of dementia compared to patients treated with insulin, metformin, or older GLP-1 agonists. These findings, publicly released on Tuesday, come as researchers and clinicians continue to search for effective means to mitigate the growing dementia epidemic in the U.S. Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. Photo by Steve Christo - Corbis/Corbis via Getty Images Why It Matters With over 6 million Americans diagnosed with dementia and more than 100,000 related deaths each year, the potential for semaglutide to meaningfully lower risk could have sweeping public health implications. Dementia does not have a cure, and nearly half of all cases are thought to be preventable by addressing risk factors like obesity, type 2 diabetes, and cardiovascular disease, the New York Post reported. Evidence supporting semaglutide's neuroprotective effects may inform future prevention strategies among high-risk populations in the U.S. What To Know Landmark Study Shows Sharp Risk Reduction Researchers at Case Western Reserve School of Medicine, National Institutes of Health and the MetroHealth System in Cleveland examined the health records of 1,710,995 U.S. patients with type 2 diabetes who had no prior diagnosis of Alzheimer's disease-related dementia (ADRD). The study used a statistical method simulating a randomized clinical trial, comparing dementia diagnoses among those prescribed semaglutide, insulin, metformin, and older GLP-1 receptor agonists. Patients treated with semaglutide had a 46 percent lower risk of developing ADRD than those receiving insulin, a 33 percent lower risk than those on metformin, and a 20 percent lower risk than those on earlier GLP-1 agonists. The effect was particularly pronounced for vascular dementia, one of the most common subtypes. No protective association was found for frontotemporal dementia or Lewy body dementia. Wide Demographic Impact Observed The protective association was consistent among subgroups, including younger and older patients, men and women, and those with and without obesity. Researchers found the risk reduction was especially evident among older adults and women. What is Semaglutide? Semaglutide is a glucagon-like peptide-1 receptor agonist that helps regulate blood sugar, lowers body weight, and offers cardiovascular benefits for patients with diabetes. The drug can help improve insulin sensitivity, protect blood vessels, and reduce inflammation in the brain. Important Study Limitations Authors acknowledged limitations, including reliance on administrative diagnosis codes, which are subject to underdiagnosis and misclassification, data on medication adherence, cognitive test scores, and genetic risk factors were unavailable. Variations in clinical practice and health care use variations could also affect findings. Researchers emphasized the need for preclinical and clinical studies to establish causal effects. Additional International Data A separate study by Oxford University, published in Lancet's eClinicalMedicine journal, analyzed more than 100 million U.S. medical records and found that Ozempic users experienced lower rates of cognitive decline and nicotine use compared to those on other diabetes medications. This study also did not find a higher risk of anxiety, depression, or other neurological and psychiatric conditions with Ozempic. The researchers emphasized that the results were limited to diabetic patients and require more rigorous randomized controlled trials. What People Are Saying The researchers of the study, in a news article published by the American Journal of Managed Care: "In a real-world population with T2D [type 2 diabetes] who had no prior diagnosis of AD/ADRD [Alzheimer disease/Alzheimer disease-related dementia], our study shows that semaglutide was associated with a significantly lower risk of overall ADRD incidence compared with other antidiabetic medications, including insulin, metformin, and other GLP-1RAs. Significant reductions were observed in older and younger patients, women and men, and patients with and without obesity." Howard Fillit, chief science officer of the Alzheimer's Drug Discovery Foundation, in comments to Reuters: "The answer to all those limitations is to do a randomized clinical trial, which is exactly what Novo is doing." What Happens Next Novo Nordisk, the maker of Ozempic, began testing semaglutide in patients with early Alzheimer's disease in 2021. The results are expected sometime this year. Do you have a story that Newsweek should be covering? Do you have any questions about this story? Contact LiveNews@
Miami Herald
25-06-2025
- Health
- Miami Herald
Study claims Ozempic may also help reduce dementia risk
By Stephen Beech Weight loss drug Ozempic may also reduce the risk of dementia, suggests a new study. American researchers found that semaglutide - the active ingredient in Ozempic and another weight loss medication, Wegovy - may lower the risk of dementia in people with type 2 diabetes. Scientists say that dementia occurs when brain cells are damaged and their connections stop working properly. That damage, which worsens over time, can be caused by various modifiable factors, including obesity, diabetes, cardiovascular diseases, traumatic brain injury and stroke. Previous research has indicated that 45% of dementia cases could be prevented by addressing modifiable risk factors. The new study suggests type 2 diabetes patients taking semaglutide had a "significantly lower" risk of developing dementia compared to other antidiabetic medications. The results were more "profound" in women and older adults, according to the findings published in the Journal of Alzheimer's Disease. Semaglutide, a glucagon-like peptide receptor (GLP-1R) molecule that decreases hunger and helps regulate blood sugar in diabetes, has previously shown several health benefits, including reductions in cardiovascular diseases. Researchers at Case Western Reserve School of Medicine in Cleveland, Ohio, analyzed three years of electronic records of nearly 1.7 million American type 2 diabetes patients. The team used a statistical approach that mimics a randomised clinical trial. They found patients prescribed semaglutide had a "significantly" lower risk for Alzheimer's disease-related dementia, compared to those who had taken any of seven other anti-diabetic medications, including other types of GLP-1R-targeting medications. Study leader Professor Rong Xu said: "There is no cure or effective treatment for dementia, so this new study provides real-world evidence for its potential impact on preventing or slowing dementia development among at-risk populations." Although the findings potentially support the idea that semaglutide could prevent dementia, Prof Xu says the study's limitations restrict the team from making firm causal conclusions. She added: "Our results indicate that research into semaglutide's use for dementia prevention will need to be further investigated through randomised clinical trials." The post Study claims Ozempic may also help reduce dementia risk appeared first on Talker. Copyright Talker News. All Rights Reserved.
